Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2007

ProBioGen and Minapharm Ink Development and Co-Promotion Agreements

  • ProBioGen and Minapharm signed separate deals to develop two therapeutic proteins. This includes one exclusively for Minapharm and a second-generation biopharmaceutical product for co-promotion.

    In the first agreement, ProBioGen will apply its cell-generation process for biopharmaceutical cell lines. Minapharm, via its subsidiary, Rhein-Minapharm-Biogenetics, will carry out the pertinent process R&D, production, and commercialization of the target therapeutic proteins.

    In the second transaction, ProBioGen and Minapharm will co-develop the product using either ProBioGen's preoptimized CHO cell line or its human neuronal cell line—AGE1.HN. Minapharm will exclusively market the product in Middle Eastern and African countries. ProBioGen will have promotional rights in rest of the world. The companies will share the revenue from the product.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »